Sulfobutyl-β-cyclodextrin sodium (SBE-β-CD) is a derivative of β-cyclodextrin with negatively charged side chains, which exerts specific interactions with positively charged drugs. It can improve the water solubility of hydrophobic drugs after encapsulation and enhance their absorption in the human body, thus improving stability and other properties. Additionally, it can form non-covalent complexes with drug molecules, thereby enhancing drug safety, reducing renal toxicity, mitigating drug hemolysis, controlling drug release rates, and masking unpleasant odors. SBE-β-CD has been applied in injectable drugs, oral drugs, nasal drugs, and ocular drugs, exhibiting special affinity and encapsulation properties for nitrogen-containing drugs. Currently, FDA-approved SBE-β-CD inclusion compounds for injection mainly include voriconazole (trade name: Vfend), ziprasidone (trade name: Geodon), and posaconazole (trade name: Noxafil).
Shandong Binzhou Zhixuan Biotechnology Co., Ltd. is a technology-driven company specializing in the research and production of cyclodextrin and its derivative series as pharmaceutical excipients, as well as additives for food, health products, and cosmetics. The company's main products include hydroxypropyl beta-cyclodextrin and sulfobutyl beta-cyclodextrin sodium salt. Moreover, the company maintains close cooperation with domestic and foreign universities and research institutions and has obtained FDA registration for its products. With a focus on research and precision, we are committed to providing you with high-quality products and services. Zhixuan is willing to cooperate with you for mutual benefit and win-win outcomes.
